Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Dx, Denver Health Medical Center Awarded $5M for Microbial MDx Development

 

NEW YORK (GenomeWeb) – The National Institutes of Health has awarded Denver Health Medical Center and Accelerate Diagnostics a five-year, $5 million grant to develop a test for detecting common bacteria directly from blood, the company announced on Friday. 

The test will also be developed to detect antibiotic resistance and to provide results in less than three hours. The initial focus of the project will be on carbepenem-resistant Enterobacteriaceae, the partners said. 

Accelerate's ID/AST System will be used for the study. Combining rapid genomic identification and high-speed phenotypic susceptibility, the platform can extract single bacteria cells from a patient's blood. Accelerate noted that current methods can take up to three days to grow a bacterial sample and to test which antibiotics are effective. 

Its CEO Lawrence Mehren recently said that Accelerate plans to launch its platform in Europe this year and to start clinical trials for the system in preparation of a 510(k) submission to the US Food and Drug Administration. 

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.